Karp J E, Burke P J, Humphrey R L
Blood. 1977 Jun;49(6):925-34.
Sequential sera from 45 patients with multiple myeloma (MM) and from 6 patients with solid tumors but normal bone marrows who received cyclophosphamide, 15 mg/kg/day for 4 days, were assayed for their effects on tritiated thymidine (3H-TdR) incorporation by normal bone marrow cells and malignant plasma cells. Pretreatment sera from 23 of the 45 patients with MM inhibited normal marrow cell proliferation relative to the effects of normal sera. Of these 45 sera, 30 inhibited plasma cell proliferation. This humoral inhibition was overcome by the induction of humoral stimulation at a predictable time during chemotherapy. The sera obtained sequentially from patients with MM and patients with normal bone marrows increased 3H-TdR uptake by both cell types by days 12-15 of therapy. Sequential changes in malignant marrow plasma cell 3H-TdR labeling indices paralleled the changes in serum activity, with an increased tumor cell growth fraction occurring at the time of peak serum stimulatory activity. The relationship between serum stimulation and malignant plasma cell proliferation was confirmed in vitro.
对45例多发性骨髓瘤(MM)患者以及6例实体瘤但骨髓正常且接受环磷酰胺治疗(15mg/kg/天,共4天)的患者的系列血清,检测其对正常骨髓细胞和恶性浆细胞掺入氚标记胸腺嘧啶核苷(3H-TdR)的影响。45例MM患者中,23例的预处理血清相对于正常血清抑制了正常骨髓细胞增殖。在这45份血清中,30份抑制了浆细胞增殖。在化疗过程中可预测的时间诱导体液刺激可克服这种体液抑制。在治疗的第12 - 15天,MM患者和骨髓正常患者的系列血清均增加了两种细胞类型对3H-TdR的摄取。恶性骨髓浆细胞3H-TdR标记指数的系列变化与血清活性变化平行,在血清刺激活性峰值时肿瘤细胞生长分数增加。血清刺激与恶性浆细胞增殖之间的关系在体外得到了证实。